Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06663631 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study on Hibernation-like Therapy Based on Mechanical Thrombectomy

Study acronym: CHILL-1
StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 20, 2024 (before its estimated January 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date changed from estimate of Nov 2024 to Nov 9, 2024v3
  2. Trial status: Not Yet Recruiting to Recruitingv2 Show 7 more changesShow less
    • Primary endpoints: 3 to 1
    • Study sites: 0 to 1
    • Interventions: Hibernation drug (Drug), Placebo group (Drug) to Placebo group (Drug), chlorpromazine and promethazine (Drug), endovascular thrombectomy (Procedure), rt-PA (Drug)
    • Eligibility criteria shortened, about 44 words
    • Secondary endpoints: 2 to 3
    • Study description expanded, about 16 words
    • Publications: details revised at 9 of 9 entries
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to learn whether chlorpromazine and promethazine（C+P）is safe in Acute Ischemic Stroke（AIS) patients and determine the maximum dosage. It will also evaluate the preliminary efficacy of C+P in AIS. The main questions it aims to answer are: What is the optimal dosage of C+P that is safe without causing adverse effects in AIS patients? What is the optimal dosage of C+P that potentially works to treat AIS? Researchers will compare C+P with placebo (saline solution without C+P) to see if C+P is safe and effective in treating Acute Ischemic Stroke. Participants will: Receive C+P or placebo at the same time as endovascular thrombectomy begins. Patients will be observed for 72 hours to see if there were any adverse effects related to C+P. Infarct volumes will be evaluated using Computed Tomography. Functional outcomes will be assessed at 90 days.
Trial Details
NCT Number NCT06663631
Lead Sponsor Capital Medical University
Collaborators: Linyi People's Hospital
Conditions
(from sponsor)		 Acute Ischemic Stroke
Related terms Ischemic Stroke
Enrollment 32 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov